Expression of microRNAs-106b in nonsmall cell lung cancer

• Published in: Journal of cancer research and therapeutics 2018-06, Vol.14 (9), p.295-298
• Main Authors: Li, Yuan, Tian, Jing, Guo, Zi-Jian, Zhang, Zhu-Bo, Xiao, Chang-Yan, Wang, Xiao-Chun
• Format: Article
• Language: English
• Subjects: Analysis; Biomarkers, Tumor - genetics; Cancer therapies; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - secondary; Cell cycle; Development and progression; Female; Follow-Up Studies; Gene expression; Gene Expression Regulation, Neoplastic; Humans; Kinases; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Lymphatic Metastasis; Lymphatic system; Male; Medical prognosis; Metastasis; MicroRNA; MicroRNAs; MicroRNAs - genetics; Middle Aged; Neoplasm Invasiveness; Non-small cell lung cancer; Patients; Polymerase chain reaction; Prognosis; RNA polymerase; Statistical analysis; Studies; Survival Rate; Tumors
• ISSN: 0973-1482; 1998-4138
• DOI: 10.4103/0973-1482.235344

Aim: To explore the expression of microRNA-106b (miRNA-106b) in nonsmall cell lung cancer (NSCLC). Settings and Design: miRNAs are short regulatory RNAs that negatively modulate gene expression at the posttranscriptional level, and are deeply involved in the pathogenesis of several types of cancer. miRNA-106b has been shown to play an oncogenic role in tumor progression. The expression of miRNA-106b is detected in this study. Subjects and Methods: Quantitative reverse transcription polymerase chain reaction and Northern blotting were used to detect the expression level of miRNA-106b in 200 NSCLC samples. Statistical Analysis Used: All statistical analyses were performed using SPSS 16.0 software. Results were statistically evaluated using the Kruskal-Wallis test and Mann-Whitney U-test. Survival curves were estimated by the Kaplan-Meier method and P < 0.05 was considered to be statistically significant. Results: miRNA-106b expression is increased in NSCLC tissues. Statistical analysis showed that overexpression of miRNA-106b was strongly associated with lymph node metastasis, stage of tumor node metastasis classification, and poor prognosis. Moreover, there was a significant difference in the miRNA-106b expression levels between smoking and nonsmoking patients. Multivariate Cox regression analysis showed that miRNA-106b was an independent prognostic factor for NSCLC patients. Conclusions: These data suggest that aberrantly expressed miRNA-106b may contribute to the development of NSCLC.